Pulmonary Cell News Volume 10.02 | Jan 21 2021

May 12, 2022

2020-21-01 | PULCN 10.02

Pulmonary Cell News by STEMCELL Technologies

Vol. 10.02 – 21 January, 2021

TOP STORY

Patterns
of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities

Using tumor expression data and non-negative matrix factorization, scientists identified four small cell lung cancer (SCLC) subtypes defined largely by differential expression of transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factor signatures accompanied by an Inflamed gene signature.
[Cancer Cell]

Abstract Graphical Abstract

On-demand Webinar on Studying Cystic Fibrosis using Primary Human Nasal Epithelial Cells - Watch Now

PUBLICATIONSRanked by the impact factor of the journal

Secretoglobin 3A2 Eliminates Human Cancer Cells through Pyroptosis

Researchers showed that secretoglobin 3A2 exhibited marked anti-cancer activity against 5 out of 11 of human NSCLC cell lines in mouse xenographs, while no effect was observed in 6 of 6 small cell lung cancer cell lines examined.
[Cell Death Discovery]

Full Article

miR-558
Reduces the Damage of HBE Cells Exposed to Cigarette Smoke Extract by Targeting TNFRSF1A and Inactivating TAK1/MAPK/NF-κB Pathway

Up-regulation of miR-558 alleviated cigarette smoke extract (CSE)-induced damage on HBE cells. The alleviative effect of miR-558 mimic on CSE-induced damage was suppressed by miR-558/TNF receptor superfamily member 1A (TNFRSF1A) overexpression.
[Immunological Investigations]

Abstract

LUNG CANCER

CKAP2L
Promotes Non-Small Cell Lung Cancer Progression through Regulation of Transcription Elongation

Through an RNAi screen performed on genes involved in chromosomal instability and overexpressed in human lung adenocarcinoma samples, scientists identified the cytoskeleton-associated protein 2-like as a potential oncogene that promotes lung cancer proliferation and growth in vitro and in vivo.
[Cancer Research]

Abstract

Long
Non-Coding RNA linc00665 Inhibits CDKN1C Expression by Binding to EZH2 and Affects Cisplatin Sensitivity of NSCLC Cells

Researchers report that lncRNA linc00665 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues. Linc00665 affected the sensitivity of NSCLC cells to the chemotherapy drug cisplatin, making it a potential target for the treatment of NSCLC.
[Molecular Therapy-Nucleic Acids]

Abstract Graphical Abstract

Autophagy
Augments the Self-Renewal of Lung Cancer Stem Cells by the Degradation of Ubiquitinated p53

By generating stable human lung cancer stem cell (CSC) cell lines with the wild-type TP53, as well as cell lines in which TP53 was deleted, the authors showed that autophagy augmented the stemness of lung CSCs by degrading ubiquitinated p53.
[Cell Death & Disease]

Full Article

EEF1A2
Interacts with HSP90AB1 to Promote Lung Adenocarcinoma Metastasis via Enhancing TGF-β/SMAD Signaling

Scientists report that eukaryotic protein translation elongation factor 1α2 (EEF1A2) mediated the epithelial–mesenchymal transformation, to promote the metastasis of lung adenocarcinoma cells in vitro and in vivo.
[British Journal of Cancer]

Full Article

Chitosan
Oligosaccharide Modified Liposomes Enhance Lung Cancer Delivery of Paclitaxel

CP50-liposomes (LSs) and CP20-LSs displayed significantly enhanced cellular uptake in A549 cells in vitro as well as superior tumor accumulation in vivo compared with non-chitosan oligosaccharide modified liposomes.
[Acta Pharmacologica Sinica]

Abstract

LncRNA
GAS6-AS2 Promotes Non-Small-Cell Lung Cancer Cell Proliferation via Regulating miR-144-3p/ MAPK6 Axis

GAS6-AS2 was identified, and its roles as well as mechanisms in regulating proliferation of NSCLC cells were investigated.
[Cell Cycle]

Abstract

Grow Functional Airway Organoids with PneumaCult™

REVIEWS

The
Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer (NSCLC)

Few treatments are available for KRAS mutant NSCLC patients, and several approaches are being tested in clinicals trials to fill this void. The authors review promising therapeutics tested for KRAS mutant NSCLC.
[Cell Reports Medicine]

Full Article Graphical Abstract

INDUSTRY AND POLICY NEWS

Lixte Biotechnology and City of Hope to Initiate Phase Ib Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

Lixte Biotechnology Holdings, Inc. announced an agreement on a Phase Ib clinical trial with City of Hope. The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease SCLC.
[Lixte Biotechnology Holdings, Inc. (GlobeNewswire, Inc.)]

Press Release

FDA
Grants Priority Review to Genentech’s Esbriet (Pirfenidone) for Unclassifiable Interstitial Lung Disease

Genentech announced that the FDA has accepted the company’s supplemental New Drug Application and granted Priority Review for Esbriet^® for the treatment of unclassifiable interstitial lung disease.
[Genentech]

Press Release

FEATURED EVENT

Patterns
of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities

Secretoglobin 3A2 Eliminates Human Cancer Cells through Pyroptosis

miR-558
Reduces the Damage of HBE Cells Exposed to Cigarette Smoke Extract by Targeting TNFRSF1A and Inactivating TAK1/MAPK/NF-κB Pathway

CKAP2L
Promotes Non-Small Cell Lung Cancer Progression through Regulation of Transcription Elongation

Long
Non-Coding RNA linc00665 Inhibits CDKN1C Expression by Binding to EZH2 and Affects Cisplatin Sensitivity of NSCLC Cells

Autophagy
Augments the Self-Renewal of Lung Cancer Stem Cells by the Degradation of Ubiquitinated p53

EEF1A2
Interacts with HSP90AB1 to Promote Lung Adenocarcinoma Metastasis via Enhancing TGF-β/SMAD Signaling

Chitosan
Oligosaccharide Modified Liposomes Enhance Lung Cancer Delivery of Paclitaxel

LncRNA
GAS6-AS2 Promotes Non-Small-Cell Lung Cancer Cell Proliferation via Regulating miR-144-3p/ MAPK6 Axis

The
Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer (NSCLC)

Lixte Biotechnology and City of Hope to Initiate Phase Ib Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

FDA
Grants Priority Review to Genentech’s Esbriet (Pirfenidone) for Unclassifiable Interstitial Lung Disease

AACR: COVID-19 and Cancer

> See All Events

Postdoctoral Fellow – Cancer Metabolism

Scientific
Communities & Communications Specialist

Postdoctoral Fellowship – Stem Cell Biology/Lung Biology

Postdoctoral
Fellowship – Lung Cancer Research

Postdoctoral Fellow Position – Host-Pathogen Interactions

> See All Jobs